Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline and ...

In cohort 1, the most common first-line treatments were tyrosine kinase inhibitors (TKI; 78.8%), followed by mammalian target of rapamycin (mTOR) inhibitors (12.4%), the investigators reported in ...